

1 Site-Selective Nucleation and Size Control of Gold Nanoparticle 2 Photothermal Antennae on the Pore Structures of a Virus


3 Candace E. Benjamin,[†] Zhuo Chen,[†] Peiyuan Kang,[§] Blake A. Wilson,[†] Na Li,[†] Steven O. Nielsen,[†]
4 Zhenpeng Qin,^{*,‡,§,||} and Jeremiah J. Gassensmith^{*,†,‡}

5 [†]Department of Chemistry and Biochemistry, [‡]Department of Biomedical Engineering, [§]Department of Mechanical Engineering,
6 The University of Texas at Dallas 800 West Campbell Road, Richardson, Texas 75080-3021, United States

7 ^{||}Department of Surgery, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390,
8 United States

9 **S** Supporting Information

10 **ABSTRACT:** In this Article, we show that the surface of the
11 bacteriophage $\Phi\beta$ is equipped with natural ligands for the
12 synthesis of small gold nanoparticles (AuNP). By exploiting
13 disulfides in the protein secondary structure and the geometry
14 formed from the capsid quaternary structure, we find that we
15 can produce regularly arrayed patterns of ~ 6 nm AuNPs
16 across the surface of the virus-like particle. Experimental and
17 computational analyses provide insight into the formation and
18 stability of this composite. We further show that the
19 entrapped genetic material can hold upward of 500 molecules
20 of the anticancer drug Doxorubicin without leaking and
21 without interfering with the synthesis of the AuNPs. This
22 direct nucleation of nanoparticles on the capsid allows for
23 exceptional conduction of photothermal energy upon nanosecond laser irradiation. As a proof of principle, we demonstrate that
24 this energy is capable of rapidly releasing the drug from the capsid without heating the bulk solution, allowing for highly
25 targeted cell killing in vitro.



26 ■ INTRODUCTION

27 The explosive growth in the synthesis of inorganic materials,
28 specifically plasmonic gold nanoparticles (AuNPs) with
29 controlled nanostructures, has led to several divergent
30 applications in the biomedical and materials fields.^{1–7}
31 Among the possible strategies to create homogeneously sized
32 AuNPs, biomolecular templates such as proteins,⁸ nucleic
33 acids,^{9–11} biological fibers,¹² and lipids^{13,14} have emerged,
34 because of the ordered and well-defined structures that these
35 macromolecules form. In addition to these structural
36 advantages, the utilization of biotemplates can impart addi-
37 tional characteristics to these nanomaterials, including solution
38 stability, three-dimensional architectures, molecular and
39 cellular recognition, and tunability for optimized cell
40 uptake.^{15–19} These emergent characteristics permit advanced
41 applications such as concomitant drug delivery and in vivo
42 imaging.

43 Virus-like particles (VLPs),²⁰ which are the noninfec-
44 tious^{21,22} proteinaceous nanoparticle analogues of viruses, are
45 proven templates^{23–26} for the synthesis of metal nanoparticles,
46 because they are innately monodisperse in size and can be
47 genetically modified^{27,28} or chemically functionalized^{29–31} to
48 attach stabilizing ligands or residues onto their surface with
49 atomistic precision. While there have been several instructive
50 reports on coating,³² absorbing,^{33–42} or growing large

AuNPs^{5,23,24,42–48} onto or within viral capsids using surface-
exposed residues, reports on restricting the diameter of the
nanoparticles by constraining their growth to a homogeneous
sub-7 nm size have not been forthcoming. This is an important
issue because nanoparticle size is critically linked to clearance
from blood and tissues,^{49–52} and cell-specific uptake and
distribution has been linked to nanoparticle diameter.⁵³ To
address this problem, we seek to utilize a multivalent strategy
to decorate a proteinaceous biocompatible VLP⁵⁴ with
multiple small plasmonic AuNPs. From here, these small
clustered AuNPs could serve as X-ray or positron emission
tomography (PET) contrast agents.⁵⁵ We are particularly
interested in their use as photothermal antennae as a way to
convert pulsed optical radiation to a potent yet extremely
localized external stimulus to activate drug release. Indeed, the
growth of AuNPs directly onto the protein surface should
increase the efficiency of thermal conduction following
nanosecond pulsed laser-induced heating. This improved
transfer of thermal energy into the protein by direct
templated-growth should promote more efficient thermally
induced protein denaturation, compared to traditional
bioconjugation methods used to attach gold onto protein⁷²

Received: September 27, 2018

Published: November 19, 2018

73 surfaces via spacers or synthetic ligands.⁵⁶ In addition, reports
 74 have shown^{57,58} that smaller AuNPs possess greater photo-
 75 thermal conversion efficiencies, because of their intrinsically
 76 higher absorption/extinction ratios. In principle, templated
 77 growth of small AuNPs directly onto a protein surface would
 78 mean the amount of gold necessary to induce any changes in
 79 protein structure could be reduced, decreasing the likelihood
 80 of detectable bioaccumulation even further. Finally, the use of
 81 nanosecond pulsed irradiation in this case will confine heating
 82 to only a few nanometers of the AuNP, permitting very high
 83 thermal-spatial resolution with negligible bulk heating of the
 84 solution. In this paper, we report the synthesis and character-
 85 ization of such a system using VLP *Q β* as outlined in Scheme
 86 1. The *Q β* capsid itself is an icosahedral virus with 180

Scheme 1. *Q β* Possesses 32 Pores, Each Either 1.5 or 3.0 nm in Diameter, Which Are Large Enough To Permit the Diffusion of Doxorubicin into and out of the VLP; after Loading, the Pores Then Are Capped by ~6 nm AuNPs Grown in Situ





Figure 1. *Q β* VLP is depicted as a ribbon model. The VLP has a diameter of 28 nm and contains a total of 32 pores. Depicted are one of the 20 large pores, each of which contains six disulfide bonds, and one of the 12 smaller pores, each of which contains five disulfide bonds.

specific absorption of gold by disulfide bonds was achieved by incubating *Q β* and tetrachloroauric acid in water followed by addition of the reducing agent sodium borohydride. Because the water was unbuffered, the final solution was lowered to a pH of 2 by the gold acid; as an alternative, 0.1 M potassium phosphate buffer (pH 7) was used. Once all the reagents were added to the vial, the solution was allowed to stand undisturbed for at least 2 h, during which time its color quickly changed from light red to dark red (Figure S1 in the Supporting Information). Based on ultraviolet–visible light (UV-vis) kinetic analysis following the formation of the surface plasmon, the reaction is 50% complete after 5 min and is >99% complete after 20 min (Figure S2 in the Supporting Information). After the reaction, the small amount of precipitated and unbound AuNPs were removed from the crude mixture by passing the reaction solution through a size-exclusion column. We noted that the nanoparticles in the precipitate increases as we increased the concentration of the acidic gold starting material, which we attribute to a decrease in pH and concomitant protein aggregate formation, which can no longer function as a template.

The selective growth of AuNPs on the pore structures was verified by transmission electron microscopy (TEM) (Figures S3 and S4 in the Supporting Information), which indicated that nearly every VLP contained some population of AuNPs, although it appeared that there was a fairly wide distribution of the number of AuNPs per *Q β* . The nanoparticle population dispersity prompted an investigation into the average number of nanoparticles per capsid, which was determined to be $\sim 6 \pm 3$ per *Q β* (Figure S5 in the Supporting Information), as determined by inductively coupled plasma–mass spectroscopy (ICP-MS). Dynamic light scattering (DLS) found an increase in capsid size from 23 nm to 64.83 ± 0.219 nm, which is a significant increase in the size of the capsid (Figure S19 in the Supporting Information). Negative stain was used to show the position of *Q β* , relative to the AuNPs. A crystallographic model of *Q β* was used to map the AuNPs over the surface. The micrographs shown in Figure 2 exhibit excellent correlation to the mapped pore patterns on the right. This clear association

87 identical coat proteins and contains 32 disulfide-lined pores.⁵⁹
 88 We reasoned that these proteins, linked like a daisy chain by
 89 either five or six disulfides to form a fixed pore, would act as a
 90 natural ligand^{60,61} and template for the formation of spherical
 91 gold nanoparticles upon in situ reduction of gold salts. We
 92 then show that this new composite material works as a proof-
 93 of-principle photolytically activated drug delivery vehicle. We
 94 can load the capsid with the anticancer drug Doxorubicin
 95 (Dox) noncovalently using random RNA located within the
 96 capsid as a supramolecular host, grow AuNPs over the loaded
 97 VLP and, finally, initiate release of the RNA-bound Dox from
 98 the center of the virus using nanosecond laser irradiation to
 99 disrupt the proteinaceous shell and release the drug molecules
 100 from the interior. Finally, we demonstrate highly selective drug
 101 release and cell killing of macrophage and cancer cells in vitro
 102 exclusively within the laser path while cells outside the path—
 103 even though they are in the same culture—show no drug
 104 release or death.

105 ■ RESULTS AND DISCUSSION

106 **Synthesis and Characterization of AuNP@*Q β* .** The *Q β*
 107 VLP, structurally depicted in Figure 1, is expressed as a
 108 noninfectious nanoparticle that self-assembles around random
 109 genomic material within *E. coli*. Protein crystallographic
 110 analysis reveals 20 pores at the 3-fold axis and 12 smaller
 111 pores at the 5-fold axis of symmetry. Key to our strategy is that
 112 these pores are lined with solvent-exposed disulfides and we
 113 hoped to benefit from the affinity of disulfides toward gold
 114 species. To establish an optimized protocol for site-specific
 115 growth of AuNPs, parameters including the concentrations of
 116 *Q β* and tetrachloroauric acid, reaction temperature, and
 117 incubation time were individually varied until we had
 118 minimized the formation of unstable naked gold particles.
 119 After significant optimization, the required conditions for
 120 AuNP formation turned out to be quite straightforward—




Figure 2. (A) (Left) Illustration of the relative locations of each nanoparticle on $Q\beta$. Orange dots represent AuNPs on pores facing the reader, while gray dots represent AuNPs on pores behind the VLP. (Right) TEM micrograph of AuNP@ $Q\beta$ synthesized over the pores of $Q\beta$. (B) Ultraviolet–visible light (UV-vis) analysis of $Q\beta$ only (black dashed line) and AuNP@ $Q\beta$ (red line).

160 of the AuNPs to the pore locations strongly suggests that the
161 pores themselves both selectively nucleate and control the final
162 diameter of the AuNPs. The AuNPs appear fairly mono-
163 disperse in size by TEM with a diameter of 3.6 ± 1 nm.

164 Powder X-ray diffraction (PXRD) confirmed the crystallinity
165 of the as-synthesized AuNPs in the AuNP@ $Q\beta$ composite, and
166 Rietveld refinement of the data was used to confirm that the
167 bulk as-synthesized diameters of the AuNPs is 6.2 ± 0.2 nm.
168 Regardless, both values are within published cutoff limits for
169 glomerular filtration. In addition, PXRD showed that the
170 structure type of the AuNP is face-centered cubic with the
171 space group $Fm\bar{3}m$ (Figure S6 in the Supporting Information).
172 The AuNP@ $Q\beta$ solution is a deep red color and ultraviolet–
173 visible light (UV-vis) spectra shows an absorption centered at

526 nm, which corresponds to the surface plasmon (Figure
2B). To elucidate the role of the virus in the nucleation and
growth of the AuNPs, we conducted several control experi-
ments. When the same procedure was performed in the
absence of any $Q\beta$, a dark precipitate formed in solution. This
precipitate was collected and was found to consist of spherical
AuNPs, as determined by X-ray diffraction and confirmed by
transmission electron microscopy (TEM), with a diameter of
 48 ± 10 nm (as shown in Figure S6).

To confirm that the disulfides themselves were responsible,
we prepared a solution of $Q\beta$ and first reduced the disulfides to
the free thiols and then alkylated them with 2-iodoacetimide.
We obtained the same results as when no $Q\beta$ was present in
the solution—huge particles in a black precipitate—
confirming the role of the disulfides in the controlled
nucleation (Figure S1). In our initial strategy, we assumed
that reduction of the disulfides was occurring with sodium
borohydride, but we were able to rule this out because we did
not detect any such reduction using gel electrophoresis (Figure
S8 in the Supporting Information) nor was there any
appreciable difference in the Ellman’s assay before and after
the addition of borohydride (Figure S10 in the Supporting
Information). It is important to point out that, during the
synthesis, even spectroscopically pure virus particles are not
fully oxidized—that is to say, it appears from nonreducing
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) that monomeric proteins exist when there
should be none^{62,63} (Figure S9 in the Supporting Information).
Curiously, reducing the disulfides to free sulfurs also fails to
yield AuNP formation on the surface of the virus. Nevertheless,
based on these experiments, it is quite evident that nucleation
and size control is occurring as a result of the disulfide and
pore geometry, as we get uncontrolled particle growth in their
absence.

AuNP@ $Q\beta$ are stable at room temperature for more than a
month when left undisturbed on the bench. TEM micrographs
(Figure S11 in the Supporting Information) of a month-old
sample that had been left under ambient laboratory conditions
show that the AuNPs are still associated with $Q\beta$, and neither
free AuNPs nor aggregation was visible. This stability is
surprising, considering that (1) the nanoparticles are
considerably larger than the pores and (2) there are only 10
or 12 S atoms bound to the nanoparticle. Based on the
TEM data, which show varying levels of contrast on the edges of the
nanoparticles, we anticipated that there were interactions
between the virus and the nanoparticles beyond simply Au–S
bonding. Therefore, we conducted computational analysis to
determine the likely changes in the local environment around
the nanoparticle. As seen in Figure 3, we modeled a 6.4 nm
nanoparticle bound to the 12 S atoms of the hexameric pore
structure. Molecular dynamics (MD) simulations provide a
reasonable picture of the actual nanoparticle–protein inter-
action. From these simulations, several intriguing results could
be inferred (see the expanded discussion of the theory in the
Supporting Information and Figures S12–S15; interestingly,
there was no significant change in the size of the hexameric
pore). However, the pore S atoms shifted radially inward,
which created a deeper cavity for the nanoparticle to sit in and,
as shown in Figure 3, allowed more of the loop structures
present near the pore to cover the surface of the nanoparticle.
Roughly 23% of the nanoparticle’s surface area was protected
by surrounding proteins, which does not significantly change
the secondary structure of the VLP, as shown by circular




Figure 3. MD simulation snapshots of $Q\beta$ with the AuNP at the hexameric pore. (A) Side view of the AuNP and surrounding proteins. The protein segments directly attached to the pore S atoms are shown in a licorice representation, while the rest of the proteins are shown as purple ribbons. (B) A snapshot that shows the pore from below. The pore S atoms are highlighted in yellow. Only the protein segments directly attached to the pore S atoms are shown.

dichroism (CD) measurements (Figure 4D). The stability provided by the surrounding proteins makes sense, because 6-nm naked AuNPs are unstable and subject to rapid Ostwald ripening, resulting in precipitation.^{41,42} Being embedded in the virus coat protein not only stabilizes these particles but also protects them—see the Supporting Information for an explanation based on classical nucleation theory and an analysis of the smaller five-membered pores.

Laser-Activated Drug Delivery. AuNPs are well-known photothermal agents and are among the best materials for converting incident optical energy into heat.⁴⁴ This heat can be dissipated diffusely into the environment by continuously irradiating the sample, which results in a heating of the bulk solution. Alternatively, heat can be generated very locally by pulsed irradiation, causing the surface of the nanoparticle to heat to several hundred degrees without significantly heating the bulk solution.⁴⁵ More than a decade ago, this latter form of pulsed irradiation was found to selectively denature proteins,⁴⁶ although, recently, the controlled application of photothermal irradiation to control protein or nucleotide function without damaging the cell has emerged as a potent method of manipulating specific cells in a culture or tissue without affecting the surrounding cells.^{56,64} Because the growth of the AuNP occurs directly onto the surface of the protein, we reasoned that, even without 100% gold coverage on each VLP, we would be able to induce a photothermal response using modest laser power. We therefore sought to determine if this mechanism could induce the disruption of the protein shell, triggering the release of entrapped small-molecule drugs. This would enable very localized drug release within a disease microenvironment without damaging nearby healthy cells.

To do this, we exploited the fact that random *E. coli* nucleotides serve as templates in the self-assembly of recombinant $Q\beta$ coat proteins to form the intact capsid. Consequently, random bacterial RNA becomes entrapped within the fully assembled VLP. We hypothesized that this genetic material could be used as a supramolecular host capable of noncovalently trapping the strong nucleotide intercalator Doxorubicin (Dox), which is a fluorescent chemotherapeutic that is used in many different cancer therapies. Binding of Dox to VLP RNA is not without precedent, as researchers have shown⁴⁷ that the RNA inside the red clover necrotic mosaic virus capsid tightly holds upward of 4300 molecules of Dox. Our tests show that the genetic material inside $Q\beta$ does the same: when Dox is bound inside the VLP, the fluorescence is modestly quenched

(Figures 4A–C and Figure S16 in the Supporting Information), and when it is released—following boiling of the capsid




Figure 4. (A) Photographs of $Q\beta$ (Dox) prior to irradiation and free Dox under 365 nm UV-light. The fluorescence is quenched in the left vial, as a result of its interaction with the genetic material entrapped in the VLP. (B) Photographs of the same vials shown in panel A under white light. (C) Fluorescence traces of $AuNP@Q\beta$ (Dox) before (black dashed line) and after (red solid line) irradiation. (D) CD spectra of $Q\beta$ and $AuNPs@Q\beta$ before (–) and after (+) laser radiation, showing reduction of CD signal after laser irradiation.

in water, for instance—it fluoresces. The association of Dox to the nucleic acids inside the $Q\beta$ is sufficiently high that, after loading, we observe no leakage, even after 24 h (Figure S17 in the Supporting Information). Thus, we can monitor the release by following any fluorescence enhancement after laser irradiation.

To create the Dox-loaded, gold-bespeckled, viral nanoparticles, we followed a procedure outlined in Scheme 1. Initially, the $Q\beta$ is loaded by incubating the VLP in a 1 mg/mL solution of Dox for 10 min at room temperature. This mixture is then filtered through a cross-linked dextran size-exclusion column to remove unbound Dox to create $Q\beta$ (Dox) (Figure S18 in the Supporting Information). The filtered solution of $Q\beta$ (Dox) was then subjected to the same procedure to grow AuNPs over the surface. This solution was again passed through a size-exclusion column to remove unattached nanoparticles and excess salts to yield pure $AuNP@Q\beta$ (Dox). By TEM, we saw no discernible difference in gold loading over the pores nor any changes in nanoparticle sizes. We were pleased to see that we could load upward of 500 molecules of Dox—as determined by UV-vis spectroscopy—without interfering with the AuNP formation on the shell.

A 70 μ L solution at a concentration of 0.04 mg/mL $AuNP@Q\beta$ (Dox) was then irradiated with a single 6-ns laser pulse at an energy density of 500 mJ/cm² and centered at a wavelength of 532 nm. The solution temperature was monitored using a

311 thermocouple and no bulk solution temperature change was
 312 observed. Based on fluorescence analysis of the irradiated
 313 sample, a 100% enhancement in fluorescence was seen,
 314 indicating that Dox was released from the capsid. Under
 315 control conditions, with no laser irradiation, no fluorescence
 316 change was observed because the Dox is tightly bound to the
 317 RNA (Figures 4A–C). In a second control, which uses
 318 convective heat, we found we could replicate these results by
 319 boiling AuNP@Q β (Dox) in water for 5 min, which completely
 320 denatured and destroyed the viral capsid. At room temper-
 321 ature, however, the AuNP@Q β (Dox) was stable for several
 322 hours and showed little variation in fluorescence. We
 323 conducted CD and DLS spectroscopic studies (Figure 4D
 324 and Figure S19 in the Supporting Information) to determine if
 325 the photothermal energy was transferred to the protein.
 326 Specifically, we looked at samples of Q β VLP with and without
 327 AuNPs to determine if any obvious change in the spectra of
 328 these samples could be ascertained. When AuNP@Q β was
 329 irradiated, a decrease and slight shift in molar ellipticity could
 330 be seen, indicating changes in secondary structure and in
 331 nanoparticle absorbance (Figure 4D), suggesting some
 332 precipitation of aggregates. Agarose band shift assays (Figure
 333 S21 in the Supporting Information) showed clear Dox release
 334 by UV imaging and a loss or change in capsid structure,
 335 following irradiation. In a control experiment using laser
 336 irradiation centered at 1064 nm, no change was evident by
 337 DLS or agarose band shift (Figures S19 and S21). We
 338 therefore attribute this heat to localized absorption of the laser
 339 light to generate thermal energy via localized surface plasmon
 340 resonance (LSPR), which, in turn, denatures the capsid
 341 proteins and provides sufficient thermal energy to release the
 342 Dox. This localized heat denaturation and drug release causes a
 343 slight shift in the nanoparticle absorbance (Figure S20 in the
 344 Supporting Information), denaturation of the protein capsid,
 345 and release of the drug, as shown by bandshift assays (Figure
 346 S21) in agarose gel electrophoresis.

347 In order to move toward studies in cellular systems, we first
 348 had to determine the toxicity of our particles via MTT assay,
 349 using each of the Q β constructs without the use of laser
 350 activation (Figure 5A). The assay found no significant cell
 351 viability difference when Q β (Dox), AuNP@Q β , and AuNP@
 352 Q β (Dox) were incubated with RAW 264.7 cells. On the other
 353 hand, the cells clearly responded to free Dox. A key advantage
 354 of this extreme confinement of thermal energy is that it should
 355 enable a highly targeted release of therapeutics exclusively
 356 within the path of a focused beam of light. In other words, we
 357 should be able to pinpoint the cells we wish to kill in a single
 358 culture without affecting the surrounding cells, because of
 359 convective heat loss. To demonstrate the efficacy of our
 360 approach in vitro, cell studies were performed using RAW
 361 264.7 macrophage and A549 lung cancer cells. For the
 362 macrophage cells, 3-cm glass bottom plates were seeded with
 363 $\sim 1 \times 10^6$ cells 1–2 days prior to the experiment producing
 364 cells that reached $\sim 80\%$ confluency. The cells were then
 365 incubated with 240 μ L of 0.2 mg/mL AuNP@Q β (Dox)—
 366 equivalent to $\sim 7.8 \mu$ M Dox, as well as appropriate controls for
 367 4 h. The cells were washed three times with PBS, stained with
 368 200 nm Hoechst 34442 and washed again with PBS. The
 369 plates were covered with a cardboard mask pierced with an 18-
 370 gauge needle to confine the laser path to a diameter of 1.27
 371 mm to demonstrate the spatial selectivity of release. The cells
 372 were then subject to a single 6-ns pulse of 500 mJ/cm² and
 373 immediately imaged by live-cell fluorescence microscopy.




Figure 5. (A) MTT assay of cells treated with Q β composites or free Dox and incubated to monitor cell viability after 4 h. Double asterisk symbol (**) and triple asterisk symbol (***) denote *P* values of ≤ 0.01 and 0.001, respectively. (B–D) Wide-field live cell images depicting Dox release after laser irradiation through a pinhole (white line indicates the perimeter of laser irradiation): (B) bright-field image, (C) blue channel showing Hoechst 34442 nuclear dye, and (D) Dox. (E) Merged images acquired with a 10 \times objective focused near the center of the plate immediately following laser exposure. Cells located close to the aperture experience the release of Dox into the cellular space while those further away do not exhibit the same release.

Immediately following laser irradiation, the release of Dox in 374
 the targeted “kill-zone” to the right of the white line in Figures 375
 5B–E was obvious in the red channel of our fluorescence 376
 microscope. The morphology of the cells, as shown in Figure 377
 5E and at higher magnification (inset), did not immediately 378
 change following irradiation, indicating that the initial laser 379

380 itself did not affect the cells (also shown in Figure S22 in the
381 Supporting Information). However, fluorescence imaging
382 revealed extensive Dox release in the kill zone with the
383 correlation between cells showing release and those within the
384 targeted area being very high; outside of this area, no red
385 fluorescence could be discerned. The highly targeted nature of
386 laser irradiation makes bulk cell viability assays such as MTT
387 ineffective; therefore, we monitored cell viability via live-cell
388 fluorescence imaging for 12 h. Cells outside the kill zone
389 remained intact and adherent, and their morphology was
390 generally unchanged. Within the kill zone, the resulting cells
391 largely detached from the plate after 12 h (Figure S23 in the
392 Supporting Information), indicating that they were killed.
393 When the experiment was repeated using 1064 nm laser light,
394 which is incapable of exciting the LSPR, the results of live cell
395 imaging clearly show no DOX release and no toxicity over that
396 same 12 h time period (Figure S24 in the Supporting
397 Information), again demonstrating that the release is attributed
398 to highly localized optical excitation of the proteinaceous gold
399 complex within the living cell. We repeated these experiments
400 on A549 cells and obtained similar results. In the case of A549
401 cells, we confirmed cell death exclusively in the laser path using
402 NucRed Dead 647 after allowing the cells to incubate for 4 h
403 (Figure S25 in the Supporting Information). Taken together,
404 these results show that we can release a supramolecularly
405 bound chemotherapeutic from random RNA using photo-
406 thermally triggered degradation of a protein complex for highly
407 localized cell killing.

408 ■ CONCLUSION

409 Using the strong affinity between disulfides and gold species,
410 we have shown that AuNPs can be synthesized site-selectively
411 in a controlled manner on the pore structures of Q β through a
412 simple incubation and reducing process. TEM micrographs
413 show a well-ordered topology of AuNP@Q β in accordance
414 with the pattern of pores on Q β . The growth of the
415 nanoparticles is clearly dependent upon the existence of
416 disulfides as reduction to free sulfurs or acylation of these
417 sulfurs fails to yield the composite material. The resulting
418 AuNP@Q β is stable, when left exposed on the benchtop at
419 room temperature for more than one month, even though the
420 AuNPs themselves are prone to self-aggregation. Computa-
421 tional modeling indicates this stability arises from surface
422 passivation by local protein physisorption. We found that the
423 growth of AuNPs on the VLP is unaffected by loading the
424 interior with the anticancer drug Doxorubicin. We successfully
425 demonstrated that this new AuNP@Q β (Dox) composite can
426 release the Dox upon nanosecond-pulsed irradiation without
427 heating the bulk solution and thus offers a pathway to drug
428 delivery with very high spatial resolution. This proof-of-
429 concept shows great promise in using laser irradiation to
430 trigger the release of materials confined within proteinaceous
431 capsids and adds another tool in the arsenal of photothermally
432 activated nanotherapeutics.

433 ■ ASSOCIATED CONTENT

434 ● Supporting Information

435 The Supporting Information is available free of charge on the
436 ACS Publications website at DOI: 10.1021/jacs.8b10446.

437 Detailed experimental and synthetic procedures as well
438 as the characterization of the materials presented in this
439 work (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: zhenpeng.qin@utdallas.edu (Z. Qin).

*E-mail: gassensmith@utdallas.edu (J. J. Gassensmith).

ORCID

Candace E. Benjamin: 0000-0002-9211-718X

Zhuo Chen: 0000-0001-7775-7579

Steven O. Nielsen: 0000-0003-3390-3313

Zhenpeng Qin: 0000-0003-3406-3045

Jeremiah J. Gassensmith: 0000-0001-6400-8106

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

C.E.B. thanks the National Science Foundation Graduate Research Fellows Program (No. 1746053) for their support. J.J.G. acknowledges the National Science Foundation (No. DMR-1654405) and the Cancer Prevention and Research Institute of Texas (CPRIT) (No. RP170752). Z.Q. acknowledges support from the National Science Foundation (No. 1631910) and CPRIT (No. RP160770).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Professor M. G. Finn and his student Jenny for their helpful advice, guidance, and generous donation of the Q β plasmid.

■ ABBREVIATIONS

VLP, virus-like particle; Dox, Doxorubicin; AuNP, gold nanoparticle; CD, circular dichroism; MD, molecular dynamics; TEM, transmission electron microscopy; PXRD, powder X-ray diffraction; EPR, enhanced permeability and retention

■ REFERENCES

- (1) Mao, C.; Solis, D. J.; Reiss, B. D.; Kottmann, S. T.; Sweeney, R. Y.; Hayhurst, A.; Georgiou, G.; Iverson, B.; Belcher, A. M. Virus-Based Toolkit for the Directed Synthesis of Magnetic and Semiconducting Nanowires. *Science* **2004**, *303* (5655), 213–217.
- (2) Bromley, K. M.; Patil, A. J.; Perriman, A. W.; Stubbs, G.; Mann, S. Preparation of high quality nanowires by tobacco mosaic virus templating of gold nanoparticles. *J. Mater. Chem.* **2008**, *18* (40), 4796–4801.
- (3) Fernandes, R.; Li, M.; Dujardin, E.; Mann, S.; Kanaras, A. G. Ligand-mediated self-assembly of polymer-enveloped gold nanoparticle chains and networks. *Chem. Commun.* **2010**, *46* (40), 7602–7604.
- (4) Mann, S. Self-assembly and transformation of hybrid nano-objects and nanostructures under equilibrium and non-equilibrium conditions. *Nat. Mater.* **2009**, *8* (10), 781–792.
- (5) Zhou, K.; Zhang, J.; Wang, Q. Site-Selective Nucleation and Controlled Growth of Gold Nanostructures in Tobacco Mosaic Virus Nanotubulars. *Small* **2015**, *11* (21), 2505–2509.
- (6) Shenton, W.; Davis, S. A.; Mann, S. Directed Self-Assembly of Nanoparticles into Macroscopic Materials Using Antibody–Antigen Recognition. *Adv. Mater.* **1999**, *11* (6), 449–452.
- (7) Li, F.; Wang, Q. Fabrication of Nanoarchitectures Templated by Virus-Based Nanoparticles: Strategies and Applications. *Small* **2014**, *10* (2), 230–245.

- 498 (8) Xie, J.; Zheng, Y.; Ying, J. Y. Protein-Directed Synthesis of
499 Highly Fluorescent Gold Nanoclusters. *J. Am. Chem. Soc.* **2009**, *131*
500 (3), 888–889.
- 501 (9) Lim, D.-K.; Jeon, K.-S.; Hwang, J.-H.; Kim, H.; Kwon, S.; Suh, Y.
502 D.; Nam, J.-M. Highly uniform and reproducible surface-enhanced
503 Raman scattering from DNA-tailorable nanoparticles with 1-nm
504 interior gap. *Nat. Nanotechnol.* **2011**, *6* (7), 452–460.
- 505 (10) Samson, J.; Piscopo, I.; Yampolski, A.; Nahirney, P.; Parpas, A.;
506 Aggarwal, A.; Saleh, R.; Drain, C. M., Fabrication of Size-Tunable
507 Metallic Nanoparticles Using Plasmid DNA as a Biomolecular
508 Reactor. *Nanomaterials* **2011**, *1* (1), 6478
- 509 (11) Raeesi, V.; Chou, L. Y. T.; Chan, W. C. W. Tuning the Drug
510 Loading and Release of DNA-Assembled Gold-Nanorod Super-
511 structures. *Adv. Mater.* **2016**, *28* (38), 8511–8518.
- 512 (12) Scheibel, T.; Parthasarathy, R.; Sawicki, G.; Lin, X.-M.; Jaeger,
513 H.; Lindquist, S. L. Conducting nanowires built by controlled self-
514 assembly of amyloid fibers and selective metal deposition. *Proc. Natl.*
515 *Acad. Sci. U. S. A.* **2003**, *100* (8), 4527–4532.
- 516 (13) Patil, A. J.; Muthusamy, E.; Seddon, A. M.; Mann, S. Higher-
517 Order Synthesis of Organoclay Pipes Using Self-Assembled Lipid
518 Templates. *Adv. Mater.* **2003**, *15* (21), 1816–1819.
- 519 (14) Burkett, S. L.; Mann, S. Spatial organization and patterning of
520 gold nanoparticles on self-assembled biolipid tubular templates. *Chem.*
521 *Commun.* **1996**, No. 3, 321–322.
- 522 (15) Crookes-Goodson, W. J.; Slocik, J. M.; Naik, R. R. Bio-directed
523 synthesis and assembly of nanomaterials. *Chem. Soc. Rev.* **2008**, *37*
524 (11), 2403–2412.
- 525 (16) Li, L.; Liu, J.; Yang, X.; Huang, J.; He, D.; Guo, X.; Wan, L.;
526 He, X.; Wang, K. Biomimetic synthesis of highly biocompatible gold
527 nanoparticles with amino acid-dithiocarbamate as a precursor for
528 SERS imaging. *Nanotechnology* **2016**, *27* (10), 105603.
- 529 (17) Gazit, E. Use of biomolecular templates for the fabrication of
530 metal nanowires. *FEBS J.* **2007**, *274* (2), 317–322.
- 531 (18) Huang, J.; Lin, L.; Sun, D.; Chen, H.; Yang, D.; Li, Q. Bio-
532 inspired synthesis of metal nanomaterials and applications. *Chem. Soc.*
533 *Rev.* **2015**, *44* (17), 6330–6374.
- 534 (19) de la Escosura, A.; Nolte, R. J. M.; Cornelissen, J. J. L. M.
535 Viruses and protein cages as nanocontainers and nanoreactors. *J.*
536 *Mater. Chem.* **2009**, *19* (16), 2274–2278.
- 537 (20) Chen, Z.; Li, N.; Li, S.; Dharmarwardana, M.; Schlimme, A.;
538 Gassensmith, J. J. Viral chemistry: the chemical functionalization of
539 viral architectures to create new technology. *Wiley Interdiscip. Rev.:*
540 *Nanomed. Nanobiotechnol.* **2016**, *8*, 512–534.
- 541 (21) Akahata, W.; Yang, Z.-Y.; Andersen, H.; Sun, S.; Holdaway, H.
542 A.; Kong, W.-P.; Lewis, M. G.; Higgs, S.; Rossmann, M. G.; Rao, S.;
543 Nabel, G. J. A virus-like particle vaccine for epidemic Chikungunya
544 virus protects nonhuman primates against infection. *Nat. Med.* **2010**,
545 *16* (3), 334–338.
- 546 (22) Naskalska, A.; Pyrc, K. Virus like particles as immunogens and
547 universal nanocarriers. *Pol. J. Microbiol.* **2015**, *64* (1), 3–13.
- 548 (23) Slocik, J. M.; Naik, R. R.; Stone, M. O.; Wright, D. W. Viral
549 templates for gold nanoparticle synthesis. *J. Mater. Chem.* **2005**, *15*
550 (7), 749–753.
- 551 (24) Zhou, Z.; Bedwell, G. J.; Li, R.; Bao, N.; Prevelige, P. E.; Gupta,
552 A. P22 virus-like particles constructed Au/CdS plasmonic photo-
553 catalytic nanostructures for enhanced photoactivity. *Chem. Commun.*
554 **2015**, *51* (6), 1062–1065.
- 555 (25) Aljabali, A. A. A.; Barclay, J. E.; Lomonosoff, G. P.; Evans, D. J.
556 Virus templated metallic nanoparticles. *Nanoscale* **2010**, *2* (12),
557 2596–2600.
- 558 (26) de la Escosura, A.; Verwegen, M.; Sikkema, F. D.; Comellas-
559 Aragonès, M.; Kirilyuk, A.; Rasing, T.; Nolte, R. J. M.; Cornelissen, J.
560 J. L. M. Viral capsids as templates for the production of monodisperse
561 Prussian blue nanoparticles. *Chem. Commun.* **2008**, No. 13, 1542–
562 1544.
- 563 (27) Fiedler, J. D.; Higginson, C.; Hovlid, M. L.; Kislukhin, A. A.;
564 Castillejos, A.; Manzenrieder, F.; Campbell, M. G.; Voss, N. R.;
565 Potter, C. S.; Carragher, B.; Finn, M. G. Engineered Mutations
Change the Structure and Stability of a Virus-Like Particle. *Biomacromolecules* **2012**, *13* (8), 2339–2348. 566
567 (28) Brown, S. D.; Fiedler, J. D.; Finn, M. G. Assembly of Hybrid
568 Bacteriophage Q β Virus-like Particles. *Biochemistry* **2009**, *48* (47),
569 11155–11157. 570
571 (29) Yin, Z.; Comellas-Aragones, M.; Chowdhury, S.; Bentley, P.;
572 Kaczanowska, K.; BenMohamed, L.; Gildersleeve, J. C.; Finn, M. G.;
573 Huang, X. Boosting Immunity to Small Tumor-Associated Carbohy-
574 drates with Bacteriophage Q β Capsids. *ACS Chem. Biol.* **2013**, *8* (6),
575 1253–1262. 576
577 (30) Pokorski, J. K.; Breitenkamp, K.; Liepold, L. O.; Qazi, S.; Finn,
578 M. G. Functional Virus-Based Polymer–Protein Nanoparticles by
579 Atom Transfer Radical Polymerization. *J. Am. Chem. Soc.* **2011**, *133*
580 (24), 9242–9245. 581
582 (31) Strable, E.; Finn, M. G. Chemical modification of viruses and
583 virus-like particles. In *Viruses and Nanotechnology*; Manchester, M.,
584 Steinmetz, N. F., Eds.; Current Topics in Microbiology and
585 Immunology, Vol. 327; Springer: Berlin, Heidelberg, 2009; pp 1–21. 586
587 (32) Aljabali, A. A. A.; Lomonosoff, G. P.; Evans, D. J. CPMV-
588 Polyelectrolyte-Templated Gold Nanoparticles. *Biomacromolecules*
589 **2011**, *12* (7), 2723–2728. 590
591 (33) Huang, Y.; Chiang, C.-Y.; Lee, S. K.; Gao, Y.; Hu, E. L.; Yoreo,
592 J. D.; Belcher, A. M. Programmable Assembly of Nanoarchitectures
593 Using Genetically Engineered Viruses. *Nano Lett.* **2005**, *5* (7), 1429–
594 1434. 595
596 (34) Nagakawa, K.; Niikura, K.; Suzuki, T.; Matsuo, Y.; Igarashi, M.;
597 Sawa, H.; Ijro, K. Virus Capsid Coating of Gold Nanoparticles via
598 Cysteine–Au Interactions and Their Effective Cellular Uptakes. *Chem. Lett.* **2012**, *41* (1), 113–115. 599
600 (35) Blaik, R. A.; Lan, E.; Huang, Y.; Dunn, B. Gold-Coated M13
601 Bacteriophage as a Template for Glucose Oxidase Biofuel Cells with
602 Direct Electron Transfer. *ACS Nano* **2016**, *10* (1), 324–332. 603
604 (36) Li, F.; Chen, H.; Zhang, Y.; Chen, Z.; Zhang, Z.-P.; Zhang, X.-
605 E.; Wang, Q. Three-Dimensional Gold Nanoparticle Clusters with
606 Tunable Cores Templated by a Viral Protein Scaffold. *Small* **2012**, *8*
607 (24), 3832–3838. 608
609 (37) Blum, A. S.; Soto, C. M.; Wilson, C. D.; Cole, J. D.; Kim, M.;
610 Gnade, B.; Chatterji, A.; Ochoa, W. F.; Lin, T.; Johnson, J. E.; Ratna,
611 B. R. Cowpea Mosaic Virus as a Scaffold for 3-D Patterning of Gold
612 Nanoparticles. *Nano Lett.* **2004**, *4* (5), 867–870. 613
614 (38) Li, F.; Chen, H.; Ma, L.; Zhou, K.; Zhang, Z.-P.; Meng, C.;
615 Zhang, X.-E.; Wang, Q. Insights into Stabilization of a Viral Protein
616 Cage in Templating Complex Nanoarchitectures: Roles of Disulfide
617 Bonds. *Small* **2014**, *10* (3), 536–543. 618
619 (39) Lee, H.-E.; Lee, H. K.; Chang, H.; Ahn, H.-Y.; Erdene, N.; Lee,
620 H.-Y.; Lee, Y.-S.; Jeong, D. H.; Chung, J.; Nam, K. T. Virus
621 Templated Gold Nanocube Chain for SERS Nanoprobe. *Small* **2014**,
622 *10* (15), 3007–3011. 623
624 (40) Zahr, O. K.; Blum, A. S. Solution Phase Gold Nanorings on a
625 Viral Protein Template. *Nano Lett.* **2012**, *12* (2), 629–633. 626
627 (41) Blum, A. S.; Soto, C. M.; Sapsford, K. E.; Wilson, C. D.; Moore,
628 M. H.; Ratna, B. R. Molecular electronics based nanosensors on a viral
629 scaffold. *Biosens. Bioelectron.* **2011**, *26* (6), 2852–2857. 630
631 (42) Wang, Q.; Lin, T.; Johnson, J. E.; Finn, M. G. Natural
632 Supramolecular Building Blocks. *Chem. Biol.* **2002**, *9* (7), 813–819. 633
634 (43) Vera-Robles, L. I.; González-Gracida, J.; Hernández-Gordillo,
635 A.; Campero, A. Using the M13 Phage as a Biotemplate to Create
636 Mesoporous Structures Decorated with Gold and Platinum Nano-
637 particles. *Langmuir* **2015**, *31* (33), 9188–9197. 638
639 (44) Wang, Q.; Lin, T.; Tang, L.; Johnson, J. E.; Finn, M. G.
640 Icosahedral Virus Particles as Addressable Nanoscale Building Blocks.
641 *Angew. Chem.* **2002**, *114* (3), 477–480. 642
643 (45) Sun, J.; DuFort, C.; Daniel, M.-C.; Murali, A.; Chen, C.;
644 Gopinath, K.; Stein, B.; De, M.; Rotello, V. M.; Holzenburg, A.; Kao,
645 C. C.; Dragnea, B. Core-controlled polymorphism in virus-like
646 particles. *Proc. Natl. Acad. Sci. U. S. A.* **2007**, *104* (4), 1354–1359. 647
648 (46) Tsvetkova, I. B.; Dragnea, B. G., Encapsulation of Nanoparticles
649 in Virus Protein Shells. In *Protein Cages: Methods and Protocols*; Orner,
650 B. P., Ed.; Springer: New York, 2015; pp 1–15. 651

- 635 (47) Liu, A.; Verwegen, M.; de Rooter, M. V.; Maassen, S. J.;
636 Traulsen, C. H. H.; Cornelissen, J. J. L. M. Protein Cages as
637 Containers for Gold Nanoparticles. *J. Phys. Chem. B* **2016**, *120* (26),
638 6352–6357.
- 639 (48) Liu, A.; Traulsen, C. H. H.; Cornelissen, J. J. L. M. Nitroarene
640 Reduction by a Virus Protein Cage Based Nanoreactor. *ACS Catal.*
641 **2016**, *6* (5), 3084–3091.
- 642 (49) De Jong, W. H.; Hagens, W. I.; Krystek, P.; Burger, M. C.; Sips,
643 A. J. A. M.; Geertsma, R. E. Particle size-dependent organ distribution
644 of gold nanoparticles after intravenous administration. *Biomaterials*
645 **2008**, *29* (12), 1912–1919.
- 646 (50) Chou, L. Y. T.; Zagorovsky, K.; Chan, W. C. W. DNA assembly
647 of nanoparticle superstructures for controlled biological delivery and
648 elimination. *Nat. Nanotechnol.* **2014**, *9* (2), 148–155.
- 649 (51) Longmire, M.; Choyke, P. L.; Kobayashi, H. Clearance
650 properties of nano-sized particles and molecules as imaging agents:
651 considerations and caveats. *Nanomedicine* **2008**, *3* (5), 703–717.
- 652 (52) Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle
653 design for overcoming biological barriers to drug delivery. *Nat.*
654 *Biotechnol.* **2015**, *33* (9), 941–951.
- 655 (53) Shang, L.; Nienhaus, K.; Nienhaus, G. U. Engineered
656 nanoparticles interacting with cells: size matters. *J. Nanobiotechnol.*
657 **2014**, *12* (1), 5.
- 658 (54) Singh, P.; Prasuhn, D.; Yeh, R. M.; Destito, G.; Rae, C. S.;
659 Osborn, K.; Finn, M. G.; Manchester, M. Bio-distribution, toxicity
660 and pathology of cowpea mosaic virus nanoparticles in vivo. *J.*
661 *Controlled Release* **2007**, *120* (1–2), 41–50.
- 662 (55) Zhou, C.; Hao, G.; Thomas, P.; Liu, J.; Yu, M.; Sun, S.; Öz, O.
663 K.; Sun, X.; Zheng, J. Near-Infrared Emitting Radioactive Gold
664 Nanoparticles with Molecular Pharmacokinetics. *Angew. Chem.* **2012**,
665 *124* (40), 10265–10269.
- 666 (56) Kang, P.; Chen, Z.; Nielsen, S. O.; Hoyt, K.; D'Arcy, S.;
667 Gassensmith, J. J.; Qin, Z. Molecular Hyperthermia: Spatiotemporal
668 Protein Unfolding and Inactivation by Nanosecond Plasmonic
669 Heating. *Small* **2017**, *13* (36), 1700841.
- 670 (57) Jiang, K.; Smith, D. A.; Pinchuk, A. Size-Dependent
671 Photothermal Conversion Efficiencies of Plasmonically Heated Gold
672 Nanoparticles. *J. Phys. Chem. C* **2013**, *117* (51), 27073–27080.
- 673 (58) Chen, H.; Shao, L.; Ming, T.; Sun, Z.; Zhao, C.; Yang, B.;
674 Wang, J. Understanding the Photothermal Conversion Efficiency of
675 Gold Nanocrystals. *Small* **2010**, *6* (20), 2272–2280.
- 676 (59) Golmohammadi, R.; Fridborg, K.; Bundule, M.; Valegård, K.;
677 Liljas, L. The crystal structure of bacteriophage Q β at 3.5 Å resolution.
678 *Structure* **1996**, *4* (5), 543–554.
- 679 (60) Letsinger, R. L.; Elghanian, R.; Viswanadham, G.; Mirkin, C. A.
680 Use of a Steroid Cyclic Disulfide Anchor in Constructing Gold
681 Nanoparticle–Oligonucleotide Conjugates. *Bioconjugate Chem.* **2000**,
682 *11* (2), 289–291.
- 683 (61) Hakkinen, H. The gold-sulfur interface at the nanoscale. *Nat.*
684 *Chem.* **2012**, *4* (6), 443–455.
- 685 (62) Chen, Z.; Boyd, S. D.; Calvo, J. S.; Murray, K. W.; Mejia, G. L.;
686 Benjamin, C. E.; Welch, R. P.; Winkler, D. D.; Meloni, G.; D'Arcy, S.;
687 Gassensmith, J. J. Fluorescent Functionalization across Quaternary
688 Structure in a Virus-like Particle. *Bioconjugate Chem.* **2017**, *28* (9),
689 2277–2283.
- 690 (63) Chen, Z.; Li, N.; Chen, L.; Lee, J.; Gassensmith, J. J. Dual
691 Functionalized Bacteriophage Q β as a Photocaged Drug Carrier.
692 *Small* **2016**, *12* (33), 4563–4571.
- 693 (64) Li, X.; Kang, P.; Chen, Z.; Lal, S.; Zhang, L.; Gassensmith, J. J.;
694 Qin, Z. Rock the nucleus: significantly enhanced nuclear membrane
695 permeability and gene transfection by plasmonic nanobubble induced
696 nanomechanical transduction. *Chem. Commun.* **2018**, *54* (20), 2479–
697 2482.